Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Decision Resources Stories

2013-12-17 12:26:54

Thailand Actively Engages in HTA Evaluations, and Cost Containment Measures are Expected to Increase in the Future, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Thailand remains one of the most demographically attractive pharmaceutical markets in the world, with over 99 percent of its population having...

2013-12-17 12:23:35

BURLINGTON, Mass., Dec. 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, will soon publish analysis of unmet need and commercial opportunities for developers of drugs that treat cardiovascular and metabolic diseases. (Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO) Some of the key findings in these reports include the following: -- Surveyed U.S. and European primary care...

2013-12-17 12:22:47

New Report from Decision Resources Explores Near-Term Opportunities in the U.S. Generic Drug Market BURLINGTON, Mass., Dec. 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that between 2013 and 2020, 40 blockbuster brands will lose patent exclusivity in the United States. According to the new Strategic Insights report entitled Indian Generics Manufacturers Penetrate U.S. Generics...

2013-12-16 12:24:49

New Report from Decision Resources Explores Commercial Opportunity for Rare Cancers Drug Market BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while there is drug development activity for cancer indications such as soft tissue sarcoma and acute myeloid leukemia, among others, high levels of unmet need persist for the treatment of many rare cancers....

2013-12-16 12:24:46

Older, Generic Mainstays Will Remain at the Core of Epilepsy Treatment, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market for epilepsy pharmacotherapies will expand at a rate of 2 percent annually through 2022, peaking at more than $4.1 billion in 2020. Market growth will be fueled primarily by...

2013-12-16 08:27:16

Oral 5-Aminosalicylates Will Remain the Preferred Treatment Regimen for Early Lines of Therapy, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through an examination of U.S. patient-level claims data, the TNF-alpha inhibitors drug class has experienced steady growth among recently treated Crohn's disease (CD)...

2013-12-16 08:26:08

Penetration into Tier 2 and Tier 3 Cities of China May Increase Uptake of Targeted Therapies for HCC and Drive Market Growth, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that in China, the uptake of premium-priced targeted therapies for hepatocellular carcinoma (HCC) is heavily influenced by their high cost...

2013-12-16 08:26:04

However, Novel Agents Will Face Reimbursement and Uptake Challenges if Robust Superiority over Anti-TNFs is Lacking, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, when considering the most important attributes for prescribing emerging therapies for Crohn's disease (CD) and ulcerative colitis (UC),...

2013-12-12 12:27:19

NSCLC Treatment Will Become Increasingly Personalized Due to Emergence of Novel Targeted Therapies with Companion Diagnostic Tests, According to Findings from Decision Resources BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry of twelve new therapies into the non-small-cell lung cancer (NSCLC) drug market will drive the market's growth from $4.9...

2013-12-12 08:27:35

Rapid Expansion of Drug-Treatable Population and Increasing Uptake of Premium-Priced Biologics Will Drive Market Growth, According to Findings from Decision Resources BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the colorectal cancer (CRC) market in China will grow at an annual rate of 9 percent, reaching approximately $575...